Quince Therapeutics (QNCX) Cash from Operations (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Cash from Operations of 7627000.0 for Q1 2026, up 20.56% year-over-year from 6326291.75 in Q1 2025, and up 27.23% quarter-over-quarter from 10481000.0 in Q4 2025.
Quince Therapeutics (QNCX) Cash from Operations (2018 - 2026) Analysis & Trends
Quince Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 7627000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 20.56% year-over-year to 7627000.0; the TTM figure through Mar 2026 stood at 39451000.0 (down 19.0% YoY), while the FY2025 annual figure was 41425000.0, down 29.84% from the prior year.
- Cash from Operations for Q1 2026 stood at 7627000.0, up from 10481000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3569000.0 in Q1 2023, with the low at 16091000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 7627000.0 (2026), against an average of 8428588.24.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 77.82% in 2023, then slumped 134.04% in 2024.
- Quince Therapeutics' Cash from Operations stood at 5835000.0 in 2022, then retreated by 4.16% to 6078000.0 in 2023, then retreated by 24.25% to 7552000.0 in 2024, then sank by 38.78% to 10481000.0 in 2025, then gained by 27.23% to 7627000.0 in 2026.
- Business Quant data shows QNCX's Cash from Operations at 7627000.0 in Q1 2026, 10481000.0 in Q4 2025, and 9928000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -18.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.63 Mn |
| Mar 31, 2026 | -7.63 Mn |
| Dec 31, 2025 | -10.48 Mn |
| Dec 31, 2025 | -10.48 Mn |
| Sep 30, 2025 | -9.93 Mn |
| Sep 30, 2025 | -9.93 Mn |
| Jun 30, 2025 | -11.42 Mn |
| Jun 30, 2025 | -11.42 Mn |
| Mar 31, 2025 | -9.60 Mn |
| Mar 31, 2025 | -9.60 Mn |
| Dec 31, 2024 | -7.55 Mn |
| Dec 31, 2024 | -7.55 Mn |
| Sep 30, 2024 | -7.26 Mn |
| Sep 30, 2024 | -7.26 Mn |
| Jun 30, 2024 | -8.74 Mn |
| Jun 30, 2024 | -8.74 Mn |
| Mar 31, 2024 | -8.35 Mn |
| Mar 31, 2024 | -8.35 Mn |
| Dec 31, 2023 | -6.08 Mn |
| Dec 31, 2023 | -6.08 Mn |